33399 27. Di Giacomo AM, Covre A, Finotello F et al (2019) Guadecitabine Plus Ipilimumab in Unresectable Melanoma: the NIBIT-M4 Clini- cal Trial. Clin Cancer Res 25:7351–7362. https:// doi. org/ 10. 1158/ 1078- 0432. Ccr- 19- 1335 28. Huang J, Xu J, Chen Y et al (2020) Camrelizumab versus inves- tigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 21:832–842.